Get the Stockscreener App
1,094.12
2.85%
-32.68
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,094.12, with a volume of 2.00M.
It is down -2.85% in the last 24 hours and up +28.60% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,126.80
Open:
$1127
24h Volume:
2.00M
Relative Volume:
0.66
Market Cap:
$975.20B
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
39.38
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+2.78%
1M Performance:
+28.60%
6M Performance:
+1.78%
1Y Performance:
+51.49%
1-Day Range:
$1,089.01
$1,132.66
1-Week Range:
$1,060.36
$1,149.10
52-Week Range:
$623.78
$1,149.10
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,093.60 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
225.40 | 555.59B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.90 | 386.27B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.56 | 296.11B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
184.78 | 287.42B | 60.48B | 10.40B | 8.05B | 3.3297 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly Gains Momentum as Weight-Loss Drug Access Expands - Kalkine Media
Eli Lilly and Co stock (US5324571083): shares hover near record highs as U.S. demand optimism lifts - AD HOC NEWS
LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst? - TradingView
Lilly Reopens Zepbound Access For 10 Million US Patients - TradingView
Eli Lilly (NYSE: LLY) Stock Price Gains As CVS Health Broadens Weight-Loss Drug Coverage - foreignpolicyjournal.com
Lilly's Mounjaro tops other GLP-1s for some type 2 diabetes patients - Reuters
Eli Lilly acquires three companies to boost infectious disease research and development - thepharmacist.co.uk
ASCO: Lilly debuts ‘strong’ data for potential Padcev challenger - Fierce Biotech
Jim Cramer on Eli Lilly: “Brilliant Management” - Insider Monkey
Eli Lilly (LLY) Reports Positive Phase 1b Verve-102 Study Results - Yahoo Finance Singapore
CVS restores Eli Lilly Zepbound weight loss drug coverage - Honolulu Star-Advertiser
Why Eli Lilly (LLY) Stock Is Trading Up Today - Yahoo Finance
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia - investor.lilly.com
Friday Five: ASCO arms race accelerates, Lilly pushes further into prevention, GSK's hepatitis B breakthrough…and more - FirstWord Pharma
Eli Lilly to Acquire Bothell Vaccine Company Curevo to Advance Shingles Prevention - 425business.com
Eli Lilly Jumps as CVS Expands Weight-Loss Drug Coverage - GuruFocus
Eli Lilly and Co (LLY) Shares Surge 4.0% -- What GF Score of 95 Tells Investors - GuruFocus
CVS brings back coverage for Lilly's obesity drug Zepbound - MSN
CVS Restores Coverage for Eli Lilly's Weight Loss Drugs (LLY) - GuruFocus
Eli Lilly (LLY) Showcases New Findings at ADA's 86th Scientific Sessions - GuruFocus
Eli Lilly Expands Vaccine Push with Three Acquisitions, Reuters Reports - Insider Monkey
Why Eli Lilly’s Latest Healthcare Move Is Drawing Attention? - Kalkine Media
LLY Stock Surges as CVS Health Restores Coverage for Weight Loss Drugs - GuruFocus
CVS returns Zepbound to drug plans after Lilly slashes price - MSN
Stock Market Today, May 28: Tech Stocks Rise as Snowflake Surges After $6 Billion Amazon Deal and Strong Earnings - The Motley Fool
Lilly to present phase 3 data on Foundayo, retatrutide at ADA - Investing.com
Why Is Eli Lilly Stock Surging On Thursday?Eli Lilly (NYSE:LLY) - Benzinga
Lilly's Foundayo and Zepbound to gain CVS coverage, lifting sales outlook - Endpoints News
Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care - PR Newswire
AAHI’s SLA-SE Adjuvant Technology Powers Lilly’s Acquisition of Curevo’s Next-Generation Shingles Vaccine - Caledonian Record
Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now - Yahoo Finance
Lilly stock hits high after CVS Caremark restores Zepbound coverage, adds Foundayo - Indianapolis Business Journal
CVS brings back coverage for Lilly’s obesity drug Zepbound - WKZO
New drug could be game changer for people with high cholesterolABC News - ABC News - Breaking News, Latest News and Videos
When Eli Lilly Pivots, TMED’s Strategy Wins - ETF Database
U.S. Stocks Move | Eli Lilly and Co (LLY.US) Rises Over 5% as CVS Health Restores Medicare Coverage for Weight-Loss Drug Zepbound - Moomoo
CVS obesity drug deal puts Lilly on equal footing with Novo - BioPharma Dive
Why is Eli Lilly stock surging today? By Investing.com - Investing.com Nigeria
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Why is Eli Lilly stock surging today? - Investing.com
Eli Lilly stock hits all-time high, reaching 1134.04 USD By Investing.com - Investing.com Nigeria
Eli Lilly and Co Stock (LLY) Moved Up by 3.03% on May 28: What Signal Does It Send? - TradingKey
CVS Returns Zepbound to Drug Plans After Lilly Slashes Price - Bloomberg.com
CVS Restores Eli Lilly's Zepbound to Commercial Formularies - streamlinefeed.co.ke
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,251 to $1,500 - 富途牛牛
CVS Caremark adds Zepbound and Foundayo to insurance coverage - qz.com
Eli Lilly (LLY) – Among the 10 Safe Stocks to Buy for the Long Term in 2026 - Insider Monkey
Eli Lilly (LLY) Unveils Obesity Data That Could Raise The Bar For The Entire Industry - Insider Monkey
Eli Lilly Zepbound Returns to CVS Formulary, Pre-Market Shares Rise as Much as 2% - TradingKey
Eli Lilly stock gains after CVS adds Zepbound to drug list - Investing.com
Why Wolfe Research Remains Bullish on Eli Lilly and Company (LLY) and Its Obesity Pipeline - Insider Monkey
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):